Understanding how certain proteins enhance cell death processes
Investigating the function of ZU5 domain-containing proteins as amplifiers of caspase activation
This study is looking at how certain proteins help activate important enzymes that control cell death, which could help us understand better how our immune system responds to stress and treatments like chemotherapy, potentially benefiting patients with autoimmune diseases and cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10890008 on NIH RePORTER |
What this research studies
This research investigates the role of ZU5 domain-containing proteins in amplifying the activation of caspases, which are crucial enzymes involved in programmed cell death. By examining how these proteins interact with caspase-1 and caspase-2, the study aims to uncover the mechanisms behind their activation and how they contribute to immune responses and the body's reaction to stressors like chemotherapy. Patients may benefit from insights gained about autoimmune diseases and cancers linked to misregulation of these proteins.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from autoimmune diseases or cancers that may be influenced by caspase activity.
Not a fit: Patients with conditions unrelated to caspase regulation or those not experiencing autoimmune diseases or cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating autoimmune diseases and cancers by targeting the mechanisms of cell death.
How similar studies have performed: Previous research has shown promising results in understanding the role of caspases in immune responses, suggesting that this approach could yield valuable insights.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Taabazuing, Cornelius — University of Pennsylvania
- Study coordinator: Taabazuing, Cornelius
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.